# Phase II Study of ABI-007 for Gastric Cancer

> **NCT00661167** · PHASE2 · COMPLETED · sponsor: **Taiho Pharmaceutical Co., Ltd.** · enrollment: 56 (actual)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** ABI-007

## Key facts

- **NCT ID:** NCT00661167
- **Lead sponsor:** Taiho Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2011-05
- **Final completion:** 2011-12
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2012-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00661167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00661167, "Phase II Study of ABI-007 for Gastric Cancer". Retrieved via AI Analytics 2026-08-23 from https://api.ai-analytics.org/clinical/NCT00661167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*